Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents.
10.1016/S1875-5364(22)60238-3
- Author:
Xingchen LIU
1
;
Xiaobing WANG
2
Author Information
1. Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
2. Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: xbwang@cpu.edu.cn.
- Publication Type:Review
- Keywords:
Anticancer mechanisms;
Derivatives;
Parthenolide;
Structural modification
- MeSH:
Sesquiterpenes/chemistry*;
Tanacetum parthenium/metabolism*;
Antineoplastic Agents/pharmacology*;
Plant Extracts;
Neoplasms/drug therapy*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2022;20(11):814-829
- CountryChina
- Language:English
-
Abstract:
Parthenolide (PTL) is a sesquiterpene lactone derived from medicinal plant feverfew (Tanacetum parthenium). Recent studies have demonstrated that it has multiple pharmacological activities, especially in the treatment of various hematological and solid cancers. The superior anticancer activity of PTL suggests that it has the potential to be a first-line drug. However, due to the limited physical and chemical properties, as well as bioavailability, structural modification strategies are strongly recommended to improve the anticancer activity. This review describes representative PTL derivatives obtained by different modification strategies, which are reported to exert antiproliferative activities superior to the parent compound PTL. Furthermore, we also summarize their basic mechanisms on cancer-related signaling pathways, so as to explain the potential and characteristics of PTL and its derivatives in cancer therapy.
